Other Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.OtherRespiratoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. OtherRespiratoryRead full story Post navigation Previous: Oxford BioTherapeutics signs collaboration with Bristol Myers SquibbNext: Pulmonary fibrosis drug developer Avalyn files IPO Related Stories Other Takeda and Weave Bio collaborate on AI-driven automation in drug development pharminent September 2, 2026 Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026